close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

4.390 -0.230 (-4.98%)
Streaming Delayed Price Updated: 1:46 PM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Jefferies Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Jefferies Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- 
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Pricing of Public Offering
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Proposed Public Offering of Common Stock
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.